Zuqui-Ramírez, Miguel A. http://orcid.org/0000-0003-3933-1846
Belalcazar-López, Victor M. http://orcid.org/0000-0001-8350-8202
Urenda-Quezada, Adelfia http://orcid.org/0000-0002-6305-9013
González-Rebatu y González, Alejandro http://orcid.org/0000-0001-6205-1231
Sander-Padilla, José G. http://orcid.org/0000-0002-4832-4624
Lugo-Sánchez, Laura A. http://orcid.org/0000-0003-1392-4512
Rodríguez-Vázquez, Ileana C. http://orcid.org/0000-0001-8578-3742
Rios-Brito, Kevin F. http://orcid.org/0009-0003-7012-3831
Arguedas-Núñez, María M. http://orcid.org/0000-0002-3301-2695
Canales-Vázquez, Emmanuel http://orcid.org/0009-0000-4954-0292
González-Canudas, Jorge http://orcid.org/0000-0001-7412-6499
Clinical trials referenced in this document:
Documents that mention this clinical trial
Multimodal Analgesia Approach in Acute Low Back Pain Management: A Phase III Study of a Novel Analgesic Combination of Etoricoxib/Tramadol
https://doi.org/10.1007/s40122-024-00653-y
Article History
Received: 21 May 2024
Accepted: 20 August 2024
First Online: 10 September 2024
Declarations
:
: Miguel A. Zuqui Ramírez, Victor M. Belalcazar López, Adelfia Urenda Quezada y Alejandro González Rebatu y González have no conflicts of interest to report. Jorge González Canudas, José G. Sander Padilla, Laura A. Lugo Sánchez, Ileana C. Rodríguez Vázquez, Kevin F. Rios Brito, María M. Arguedas Núñez and Emmanuel Canales Vázquez report no conflicts of interest in this work. Jorge González Canudas, José G. Sander Padilla, Laura A. Lugo Sánchez, Ileana C. Rodríguez Vázquez, Kevin F. Rios Brito, María M. Arguedas Núñez and Emmanuel Canales Vázquez are employees of Laboratorios Silanes.
: The present study was developed, until its conclusion, following the legal provisions of the General Health Law of the United Mexican States, the Official Mexican Law NOM-012-SSA3-current version, to the Official Mexican Law NOM-220-SSA1-current version, and in accordance with the Helsinki Declaration of 1964 and its later amendments. The study protocol, informed consent form (ICF), and any other relevant documents according to National Regulation were reviewed and approved by an independent ethics committee (IECs) (Research Committee of Investigación Biomédica para el Desarrollo de Fármacos, S.A. de C.V.) with the approval Number: CEI-000002, and the Health Authority (Federal Commission for the Protection against Sanitary Risks [COFEPRIS]) with the <i>approval Number: 213300410A0125/2021</i>. All patients included in this study provided written informed consent.